GB202019241D0 - Pharmaceutical composition - Google Patents
Pharmaceutical compositionInfo
- Publication number
- GB202019241D0 GB202019241D0 GBGB2019241.5A GB202019241A GB202019241D0 GB 202019241 D0 GB202019241 D0 GB 202019241D0 GB 202019241 A GB202019241 A GB 202019241A GB 202019241 D0 GB202019241 D0 GB 202019241D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (18)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/GB2021/051475 WO2021250434A1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
CN202180055398.7A CN116056762A (en) | 2020-06-12 | 2021-06-14 | Compositions comprising benzoates of 5-methoxy-N, N-dimethyltryptamine |
AU2021289147A AU2021289147A1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
EP21735380.4A EP3941904A1 (en) | 2020-06-12 | 2021-06-14 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
JP2022576811A JP2023530292A (en) | 2020-06-12 | 2021-06-14 | Compositions containing the benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
EP21735379.6A EP3941583B9 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
PCT/GB2021/051476 WO2021250435A1 (en) | 2020-06-12 | 2021-06-14 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
IL298871A IL298871A (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
EP23157604.2A EP4279070B1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
BR112022025306A BR112022025306A2 (en) | 2020-06-12 | 2021-06-14 | COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXIN, N-DIMETHYLTRIPTAMINE |
KR1020237001336A KR20230024378A (en) | 2020-06-12 | 2021-06-14 | A composition comprising the benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
CA3187020A CA3187020A1 (en) | 2020-06-12 | 2021-06-14 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
US17/660,981 US11518743B2 (en) | 2020-06-12 | 2022-04-27 | Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine |
US17/660,873 US11518742B2 (en) | 2020-06-12 | 2022-04-27 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
US17/817,548 US11603353B2 (en) | 2020-06-12 | 2022-08-04 | Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
US17/935,256 US11680044B2 (en) | 2020-06-12 | 2022-09-26 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
US18/162,976 US20230348381A1 (en) | 2020-06-12 | 2023-02-01 | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
US18/310,822 US20230382858A1 (en) | 2020-06-12 | 2023-05-02 | Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2008961.1A GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
Publications (5)
Publication Number | Publication Date |
---|---|
GB202019241D0 true GB202019241D0 (en) | 2021-01-20 |
GB2596884A GB2596884A (en) | 2022-01-12 |
GB2596884B GB2596884B (en) | 2022-09-21 |
GB2596884B8 GB2596884B8 (en) | 2023-08-09 |
GB2596884A8 GB2596884A8 (en) | 2023-08-09 |
Family
ID=71835429
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2008961.1A Ceased GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
GB2019241.5A Active GB2596884B8 (en) | 2020-06-12 | 2020-12-07 | A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2008961.1A Ceased GB202008961D0 (en) | 2020-06-12 | 2020-06-12 | Pharmaceutical composition |
Country Status (1)
Country | Link |
---|---|
GB (2) | GB202008961D0 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
HUE061482T2 (en) | 2019-11-07 | 2023-07-28 | Small Pharma Ltd | Method of synthesis |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
IL298871A (en) | 2020-06-12 | 2023-02-01 | Beckley Psytech Ltd | Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE548034T1 (en) * | 2006-06-28 | 2012-03-15 | Chelsea Therapeutics Inc | PHARMACEUTICAL COMPOSITIONS CONTAINING DROXIDOPA |
EP2720536A4 (en) * | 2011-06-16 | 2015-04-01 | Harvard College | Novel rodent control agents and uses thereof |
WO2013063492A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
-
2020
- 2020-06-12 GB GBGB2008961.1A patent/GB202008961D0/en not_active Ceased
- 2020-12-07 GB GB2019241.5A patent/GB2596884B8/en active Active
Also Published As
Publication number | Publication date |
---|---|
GB2596884B (en) | 2022-09-21 |
GB2596884A (en) | 2022-01-12 |
GB202008961D0 (en) | 2020-07-29 |
GB2596884B8 (en) | 2023-08-09 |
GB2596884A8 (en) | 2023-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB202019241D0 (en) | Pharmaceutical composition | |
IL304290A (en) | Pharmaceutical composition | |
GB201911517D0 (en) | Pharmaceutical composition | |
EP4221690A4 (en) | Pharmaceutical compositions | |
EP4230210A4 (en) | Stable pharmaceutical composition | |
IL300090A (en) | Pharmaceutical compositions comprising venglustat | |
GB201900258D0 (en) | Pharmaceutical composition | |
GB202208464D0 (en) | Pharmaceutical composition | |
EP4338730A4 (en) | Pharmaceutical composition | |
EP4238578A4 (en) | Pharmaceutical composition | |
GB202109271D0 (en) | Pharmaceutical composition | |
GB202108387D0 (en) | Pharmaceutical composition | |
GB202107518D0 (en) | Pharmaceutical composition | |
GB202105858D0 (en) | Pharmaceutical composition | |
GB202105462D0 (en) | Pharmaceutical composition | |
GB202105049D0 (en) | Pharmaceutical composition | |
GB202105047D0 (en) | Pharmaceutical composition | |
GB202104224D0 (en) | Pharmaceutical composition | |
GB202102095D0 (en) | Pharmaceutical composition | |
GB202102100D0 (en) | Pharmaceutical composition | |
GB202101640D0 (en) | Pharmaceutical composition | |
GB202101638D0 (en) | Pharmaceutical composition | |
GB202101634D0 (en) | Pharmaceutical composition | |
GB202101123D0 (en) | Pharmaceutical composition | |
GB202100711D0 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
S13A | Application for inventor to be mentioned (section 13(1)/patents act 1977) |
Free format text: APPLICATION FILED; APPLICATION UNDER RULE 10(2) FOR INVENTOR TO BE MENTIONED FILED ON 13 OCTOBER 2022 BY BECKLEY PSYTECH LIMITED |
|
S13A | Application for inventor to be mentioned (section 13(1)/patents act 1977) |
Free format text: APPLICATION ALLOWED; IN A DECISION OF THE COMPTROLLER DATED 03 AUGUST 2023, THE COMPTROLLER FOUND THAT TIMOTHY MASON SHOULD BE MENTIONED AS A JOINT INVENTOR IN RESPECT OF PUBLISHED PATENT APPLICATION AND GRANTED PATENT GB2596884. THE COMPTROLLER ORDERED THAT AN ADDENDUM SLIP BE PREPARED FOR THE PUBLISHED PATENT APPLICATION AND GRANTED PATENT ACCORDINGLY. |